Comphya Appoints Pim van Wesel as Chief Executive Officer to Lead Next Phase of Growth
19 May 2025
PRESS RELEASE
Lausanne, Switzerland – May 19, 2025 – Comphya SA, a pioneering medical device company developing the first implantable neurostimulator to restore erectile function, is pleased to announce the appointment of Pim van Wesel as Chief Executive Officer (CEO), effective June 1, 2025.
As Comphya advances its clinical development and enters a new phase of corporate growth, Pim will strengthen the leadership team by supporting fundraising efforts, business development activities, strategic partnerships, and preparing the company for future commercialization. His leadership will be instrumental in driving Comphya’s mission to deliver innovative solutions and improve patient outcomes worldwide.
Pim van Wesel brings a wealth of experience in the life sciences sector, having held senior and global leadership roles at world-class MedTech companies including Medtronic and BD. A seasoned life sciences executive with a proven track record in innovative therapy development and commercialization, Pim most recently served as Vice President & General Manager for the former AMF Medical operations, where he successfully led the company as Co-CEO. Under his leadership, AMF Medical transitioned out of stealth mode, secured multiple funding rounds, achieved Breakthrough Device Designation from the FDA, and was ultimately acquired by Tandem Diabetes Care in 2023.
Throughout his career, Pim has been dedicated to improving therapy adoption for better patient outcomes, empowering caregivers, and driving meaningful healthcare impact through strategic execution and team leadership.
As part of this leadership transition, Comphya’s current CEO and co-founder, Dr. Rodrigo Fraga, will assume the role of Chief Operating Officer (COO). In this capacity, Dr. Fraga-Silva will focus on leading the company’s clinical development, regulatory strategy, operational execution, and internal management activities. His continued leadership will be critical to supporting Comphya’s accelerated growth and ensuring the successful execution of its strategic initiatives.
“I am truly excited to welcome Pim to Comphya,” said Rodrigo Fraga, COO and co-founder of Comphya. “His outstanding leadership experience and proven success in advancing innovative therapies will be instrumental as we enter this next stage. I am very happy to work alongside him on this journey to improve the lives of patients suffering from erectile dysfunction.”
“I am honored to join Comphya at this pivotal moment,” said Pim van Wesel. “The company has developed an innovative technology with the potential to transform treatment for men suffering from ED. I look forward to working closely with Rodrigo and the talented Comphya team to bring this important therapy to patients and drive the company’s next phase of growth.”
“The Board is delighted to welcome Pim as CEO,” said Steve Swinson, Chairman of Comphya’s Board of Directors. “His strong leadership background, entrepreneurial spirit, and experience in scaling innovative MedTech companies make him the ideal leader to guide Comphya through its next chapter. We also want to recognize Rodrigo’s outstanding contributions bringing CaverSTIM technology from an idea to the clinical stage in renowned international centers, and we are pleased that he will continue to play a critical leadership role as COO.”
For more information on Comphya’s technology and clinical progress, visit www.comphya.com.
About CaverSTIM
CaverSTIM is the first implantable neurostimulator designed to restore erectile function. This innovative technology is primarily intended for patients who are non-responders to oral medications, such as post- prostatectomy patients. CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG) containing a rechargeable battery and electronics responsible for generating the electrostimulation signal. It is connected to an array of two electrodes (with multiple individual electrodes) to be implanted in the pelvic cavity, where they will activate and restore the nerves responsible for penile erection. The IPG is implanted subcutaneously in the lower abdomen and is remotely operated by external controllers. The clinician controller allows the medical expert to adjust and tailor the system parameters to best suit each patient. The patient controller enables the patient to activate the device and deliver electrical stimulation to the cavernous nerves with the aim of restoring their function.
About Comphya SA
Comphya is a medical device company based in Lausanne, Switzerland, developing CaverSTIM, the first implantable device to restore erectile function in patients non-responsive to oral drugs. Today, these patients resort to intrapenile injections or penile implants, the only available yet painful, problematic, and outdated therapies. Comphya’s patented solution offers a unique and superior treatment for erectile dysfunction. The company’s goal is to offer physiological sexual function and quality of life to large parts of the male population in great need.
For more information, visit www.comphya.com
Contact
Comphya SA
Rodrigo Fraga-Silva, PhD
CEO & co-founder
Rodrigo.Fraga@comphya.com